Psychopharmacological treatment differences in autogenous and reactive obsessions: A
retrospective chart review
Engelsk titel: Psychopharmacological treatment differences in autogenous and reactive obsessions: A
retrospective chart review
Läs online
Författare:
Batmaz, Sedat
;
Yildiz, Mesut
;
Songur, Emrah
Email: sedatbatmaz@gop.edu.tr
Språk: Eng
Antal referenser: 59
Dokumenttyp:
Artikel
UI-nummer: 16033382
Sammanfattning
Background: Identification of homogeneous subgroups of obsessive compulsive disorder (OCD)
patients may have important implications for improving effective treatment options. It has been
proposed that obsessive thoughts can be classified into two subtypes, i.e. autogenous and reactive
obsessions. Although it has been shown that patients with autogenous obsessions may display a
worse response to treatment, no studies have yet addressed whether there is a different need for the
psychopharmacological treatment options in the subtypes of OCD patients. Aim: To investigate the
clinical characteristics and treatment differences between autogenous (A-OCD) and reactive (R-OCD)
subtypes of OCD patients. Methods: Both OCD subgroups (n = 50 for A-OCD, n = 130 for R-OCD) were
compared with each other in terms of their demographic and clinical parameters. Odds ratio values
for gender, treatment options, co-morbidity, severity of OCD, and response to treatment were
computed. Multivariate hierarchical regression analyses were performed to identify any predictors for
treatment options, severity of OCD, and response to treatment. Results: Our results indicated that the
A-OCD and R-OCD groups differed from each other on some demographic and clinical variables in
addition to their psychopharmacological treatment needs. Patients in the A-OCD group were found to
be prescribed an atypical antipsychotic 2.3 times more likely than the R-OCD group. The odds for a
combination treatment, or the improvement of OCD symptoms from baseline levels did not differ
between the two subtypes of obsession groups. Conclusions: Autogenous and reactive subtypes of
obsessions may need to be offered different psychopharmacological treatment options.